Published: 13 March 2020
Author(s): Avi Leader, Vincent ten Cate, Arina J ten Cate-Hoek, Erik A.M. Beckers, Galia Spectre, Cinzia Giaccherini, Anna Gurevich-Shapiro, Eilon Krashin, Pia Raanani, Harry C. Schouten, Anna Falanga, Hugo ten Cate
Issue: July 2020
Section: Original article

Thrombocytopenia in cancer patients with an indication for anticoagulation is not uncommon [1], and poses a unique clinical challenge. Clinical trials evaluating anticoagulants for treatment of venous thromboembolism (VTE) excluded patients with thrombocytopenia [2-4]. As a result, management is informed mainly by expert opinion [5] and limited retrospective cohort studies on VTE, as recently reviewed [6]. In this setting, anticoagulation can be held or continued at full or reduced doses, with or without platelet transfusion support.

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.